We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A follow-on therapy to insulin aspart was shown to be ...

Biocon Biologics and Civica announced a strategic collaboration agreement to expand access and affordability of Insulin Aspart in the United States. Under the terms of the agreement, Biocon Biologics ...

HAMBURG, Germany -- Faster-acting insulin aspart was safe for pregnant women with type 1 or 2 diabetes and resulted in fewer events of hypoglycemia, the randomized CopenFast trial found. The mean ...

Insulin is an essential medicine that helps the body turn food into energy and regulate blood sugar levels for millions of people with diabetes nationwide. That makes access to insulin vital for ...

The active ingredient in Fiasp is insulin aspart. (An active ingredient is what makes a drug work.) Fiasp is a biologic drug, which means it’s made from living cells. Fiasp comes as a liquid solution ...

Please provide your email address to receive an email when new articles are posted on . Fast-acting insulin aspart provides similar time in range as insulin aspart for adults with type 1 diabetes ...

Novo Nordisk announced that the FDA has approved its insulin aspart injection Fiasp, which can rapidly improve glycemic control at mealtimes for patients with type 1 and type 2 diabetes. Novo Nordisk ...

The US Food and Drug Administration (FDA) has expanded the indication for the more rapid-acting version of insulin aspart (Fiasp, Novo Nordisk) for use in insulin pumps. Injectable and intravenous ...

Lannett has added a new co-development agreement for biosimilar insulin Aspart with its strategic alliance partners within the HEC Group of companies. Insulin Aspart, a short-acting (fast-acting) ...

The efficacy benefits of biphasic insulin aspart formulation (BIAsp 30) in patients with diabetes mellitus have been reported in several studies. BIAsp 30 has been shown to be more effective in terms ...

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Insulin Aspart - Comprehensive Patent Search" report to their offering. Eliminate unnecessary risk with the industry ...